To ensure Humira maintains its potency and effectiveness when you’re ready to inject it, you will need to keep it ...

The global fill finish manufacturing market is projected to grow from USD 18.36 billion in 2025 to USD 28.14 billion by 2030, ...

We explore the challenges and opportunities of eco-design in parenteral packaging, from alternative feedstocks and carbon ...

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels.

EMA committee recommends marketing approval for Lupin’s biosimilar ranibizumab: Our Bureau, Mumbai Wednesday, December 17, 2025, 14:40 Hrs [IST] Global pharma major Lupin Limite ...

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Lupin said the Committee for Medicinal Products for Human Use (CHMP) has backed the approval of the biosimilar, to be ...

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole ...

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...